The role of active vWF in physiological platelet adhesion and aggregatio
Completed
- Conditions
- von Willebrand Disease type 2BvWD 2B10064477
- Registration Number
- NL-OMON48403
- Lead Sponsor
- niversiteit Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
* 18 years or older
Exclusion Criteria
* History of thrombosis or bleeding
* Use of anti-coagulants, aspirin or other platelet function inhibitors in the 10 days preceding the blood draw for an experiment
* Use of statins and ACE inhibitors
* Diagnosis of hepatic and/or renal failure
* Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, systemic lupus erythematous (SLE), diabetes mellitus (DM)
* Malignancies (excluding basal cell carcinoma of the skin)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary study outcome is active von Willebrand factor levels, normalized to<br /><br>levels in normal pooled plasma (% of NPP), as measured by the immunosorbent<br /><br>assay.</p><br>
- Secondary Outcome Measures
Name Time Method <p>* Binding of the VHH to different forms of vWF (expressed as OD at 490 nm after<br /><br>addition of substrate OPD to reaction).<br /><br>* Ristocetin-induced vWF-platelet binding, measured by flow cytometric assay,<br /><br>expressed as median fluorescence index (MFI).<br /><br>* Ristocetin-, collagen or ADP-induced vWF-dependent platelet agglutination or<br /><br>aggregation (respectively), measured by LTA, expressed as maximal platelet<br /><br>aggregation.<br /><br>* Aperture occlusion time, as measured by PFA-200, expressed in seconds<br /><br>* Platelet covered area (%), measured from images taken during perfusion<br /><br>experiments<br /><br>* Fluorescence intensity (AU), measured from images taken during perfusion<br /><br>experiments</p><br>